We have located links that may give you full text access.
Evaluation Studies
Journal Article
Early postoperative outcome and hemodynamic performance of the sorin pericarbon stentless aortic valve.
Journal of Heart Valve Disease 2002 September
BACKGROUND AND AIMS OF THE STUDY: Stentless aortic bioprostheses offer potential advantages in terms of durability and hemodynamic performance. The study aim was to evaluate the early postoperative performance of the Sorin Pericarbon stentless bioprosthesis.
METHODS: Between November 1999 and December 2000, 34 patients (12 males, 22 females; mean age 71.2 +/- 4.8 years; range: 48-85 years) underwent aortic valve (AV) replacement with the Sorin Pericarbon stentless bioprosthesis. Twenty-two patients were in NYHA classes III-IV, and 12 were in classes I-II. Twenty-one patients had AV stenosis, nine AV regurgitation, and four mixed pathology. Doppler-echocardiography was performed before surgery, at hospital discharge and at six-month follow up. At this time, 20 patients also underwent echo-Doppler stress testing, with peak transvalvular gradient measured at rest and during exercise.
RESULTS: There were two hospital deaths (not valve-related). No significant perioperative complications were recorded. At hospital discharge, the aortic peak gradient was 15.7 +/- 10.6 mmHg; nil or trivial aortic regurgitation was found in three patients. During six months follow up no endocarditis or thromboembolic events were registered. At six months postoperatively, the transvalvular peak gradient showed a small but significant decrease (11.3 +/- 3.5 mmHg at six months, p = 0.036). Mean left ventricular mass index was also decreased significantly (118.4 +/- 28.5 versus 98.4 +/- 17.8 g/m2, p = 0.024). Left ventricular ejection fraction and effective orifice area were not changed significantly during follow up. In patients undergoing exercise testing (mean maximal workload 96 +/- 48 W), the peak aortic gradient was increased (not significantly) at exercise peak (from 14.7 +/- 6.5 to 17.2 +/- 6.7 mmHg, p = 0.086).
CONCLUSION: The excellent early postoperative outcome of this experience with the Sorin Pericarbon stentless valve encourages the use of this prosthesis. Long-term follow up and further evaluations are required with regard to hemodynamic performance and durability.
METHODS: Between November 1999 and December 2000, 34 patients (12 males, 22 females; mean age 71.2 +/- 4.8 years; range: 48-85 years) underwent aortic valve (AV) replacement with the Sorin Pericarbon stentless bioprosthesis. Twenty-two patients were in NYHA classes III-IV, and 12 were in classes I-II. Twenty-one patients had AV stenosis, nine AV regurgitation, and four mixed pathology. Doppler-echocardiography was performed before surgery, at hospital discharge and at six-month follow up. At this time, 20 patients also underwent echo-Doppler stress testing, with peak transvalvular gradient measured at rest and during exercise.
RESULTS: There were two hospital deaths (not valve-related). No significant perioperative complications were recorded. At hospital discharge, the aortic peak gradient was 15.7 +/- 10.6 mmHg; nil or trivial aortic regurgitation was found in three patients. During six months follow up no endocarditis or thromboembolic events were registered. At six months postoperatively, the transvalvular peak gradient showed a small but significant decrease (11.3 +/- 3.5 mmHg at six months, p = 0.036). Mean left ventricular mass index was also decreased significantly (118.4 +/- 28.5 versus 98.4 +/- 17.8 g/m2, p = 0.024). Left ventricular ejection fraction and effective orifice area were not changed significantly during follow up. In patients undergoing exercise testing (mean maximal workload 96 +/- 48 W), the peak aortic gradient was increased (not significantly) at exercise peak (from 14.7 +/- 6.5 to 17.2 +/- 6.7 mmHg, p = 0.086).
CONCLUSION: The excellent early postoperative outcome of this experience with the Sorin Pericarbon stentless valve encourages the use of this prosthesis. Long-term follow up and further evaluations are required with regard to hemodynamic performance and durability.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app